AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q2 2014 Earnings Presentation

25 slides from AMAG Pharmaceuticals's earnings presentation, Jul 29, 2014

  1. Slide 1: AMAG Pharmaceuticals July 29, 2014

    AMAG Pharmaceuticals July 29, 2014

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements 1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, state

  3. Slide 3: Agenda

    Agenda 2 Topic Speaker Opening Remarks Bill Heiden, CEO Feraheme and MuGard Update Bill Heiden, CEO Portfolio Expansion Frank Thomas, COO Financial Highlights & Outlook Scott Holmes, SVP of Finance and IR Closing Remarks Bill Heiden, CEO

  4. Slide 4: Building a Multi-product Specialty Pharmaceutical Company

    Building a Multi-product Specialty Pharmaceutical Company 3 Commercial Infrastructure Focus on Hematology/Oncology, Hospital and Nephrology Strong Balance Sheet Experienced Management Team Feraheme® U.S. CKD Business Feraheme IDA label Expansion* IV Iron Market Expansion Feraheme Geographic Expansio

  5. Slide 5: Second Quarter 2014 Highlights

    Second Quarter 2014 Highlights Strong 2Q14 financial performance vs. 2Q13 26% increase in total revenue U.S. Feraheme ex-factory net sales $22.2MM (up 27% vs. 2Q13) 18% volume; 9% price Wholesaler inventories minimal change Feraheme - Robust physician-level demand growth vs. 2Q13 Record provider dem

  6. Slide 6: Feraheme Update

    FERAHEME UPDATE

  7. Slide 7: Overall Feraheme Demand Growth

    Overall Feraheme Demand Growth 6 Source: IMS Health Data. *Evolution Index = Product growth divided by market growth; E.I. of 106 means Feraheme is growing 6% faster than the market in 2Q14 vs. 2Q13, taking share from competition. Market Share & E.I. 2Q14 vs. 2Q13 Hospital segment 11.4% market share

  8. Slide 8: Competitive Landscape U.S. IV Iron Market

    Competitive Landscape U.S. IV Iron Market ~900,000 Grams Annually 7 *Aggregate of Ferrlecit® Brand + Generic Ferric Gluconate 2Q14 Share of Non-dialysis Market (Grams) Venofer® Iron Dextran / Dexferrum Injectafer® * Ferric Gluconate 16.3% (vs. 15.3% in 2Q13) Source: IMS Health Data. 14.3% 43.3% 5.4%

  9. Slide 9: Today's Commercial Objective: Increase Share of Current CKD IV Iron Market

    Today’s Commercial Objective: Increase Share of Current CKD IV Iron Market 8 IDA IDA-CKD ~33% Feraheme Significant growth opportunity in current indication ~$250 million Feraheme potential (450,000 grams*) Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic

  10. Slide 10: Potential IDA Label Expansion: Broaden penetration across the entire IV Iron Market

    Potential IDA Label Expansion*: Broaden penetration across the entire IV Iron Market 9 ~$500 million Feraheme potential (900,000 grams**) IDA IDA-CKD Label Expansion Opportunity* Same call audience: Hematology/Oncology Expand use to all IDA patients in current accounts Convert single IV iron stocker

  11. Slide 11: Regulatory Update: Feraheme & Rienso

    * Pharmacovigilance Risk Assessment Committee (sub-committee of European Medicines Agency) Regulatory Update: Feraheme & Rienso Feraheme - U.S. U.S. broad IDA label 2Q14 - Held end-of-review meeting with FDA to discuss next steps from complete response letter received in 1Q14 2H14 - Determination of

  12. Slide 12: Opportunity: Grow U.S. IV Iron Market

    Opportunity: Grow U.S. IV Iron Market 11 IV Iron IDA* IV Iron IDA-CKD 4,000,000 patients diagnosed with IDA placed on oral iron therapy IV Iron IDA-CKD IV Iron IDA* Oral Iron IDA* Oral Iron IDA-CKD *If regulatory approval is pursued and received. 4,000,000 patients diagnosed with IDA placed on oral

  13. Slide 13: MuGard Update

    ~ MUGARD UPDATE

  14. Slide 14: MuGard Overview and 2Q14 Highlights

    Overview Prescription mucoadhesive for the management of oral mucositis (OM) Forms a protective coating over the oral mucosa to shield the membranes of the mouth and tongue Incremental medical care cost of severe OM in head and neck cancer patients is ~$18,000* 2Q14 Highlights Study demonstrating st

  15. Slide 15: Growing Market & Market Share

    14 *AMAG estimates market opportunity at $1,500/Rx of 6 bottles. **Source: Total RX’s IMS Health Data. ***Evolution Index = Product Growth Divided by Market Growth 2Q14: 49% Increase in Physician Demand (vs. 1Q14) Evolution Index*** (E.I.) of 122 Growing 22% faster than the market < 5% of patients a

  16. Slide 16: Portfolio Expansion

    PORTFOLIO. EXPANSION

  17. Slide 17: 5-Year Business Development Objectives

    5-Year Business Development Objectives 16 Revenues 2018 2013 Acquired Products Existing Products In-license or acquire: Commercial, revenue-generating products Late stage development assets that have significant peak sales and growth potential Leverage AMAG’s corporate infrastructure and commercial

  18. Slide 18: Business Development Targeting Strategy

    Business Development Targeting Strategy 17 Financial Revenue-generating commercial products Late-stage development assets with significant peak sales and growth potential Realize cost synergies to increase cash flows & EBITDA Optimize after-tax cash flows Products with IP runway Channel Clinic-based

  19. Slide 19: Business Development at AMAG: Defining Success

    Business Development at AMAG: Defining Success 18 Future (2018) Diversified commercial product portfolio Maturing late-stage development pipeline Potential for significant cash generation Present Two products Minimal cash burn Visibility towards positive EBITDA Past (2010) Single product Significant

  20. Slide 20: Financial Highlights & Outlook

    FINANCIAL HIGHLIGHTS & OUTLOOK

  21. Slide 21: Feraheme Ex-Factory Sales Performance

    Feraheme Ex-Factory Sales Performance 20 Ex-factory net sales* ($ in millions) * Excludes the impact of changes in estimates made to product returns and Medicaid reserves in 2012 and 2013 2Q14 vs. 2Q13 27% growth (+18% volume, +9% price)

  22. Slide 22: Second Quarter Financial Highlights

    Second Quarter Financial Highlights ($ in millions, except per share) 2Q13 2Q14 U.S. Feraheme net sales $17.5 $22.2 Total revenues $19.6 $24.8 Feraheme gross margin $14.4 $19.8 R&D expenses $4.0 $4.5 SG&A expenses $15.2 $16.3 Operating income / (loss) $(2.8) $1.2 Net loss $(1.9) $(1.5) Net loss per

  23. Slide 23: 2014 Financial Outlook

    2014 Financial Outlook ($ in millions) Original 2014 Guidance* Updated 2014 Guidance* Total revenues $88 - $100 $93 - $102 U.S. Feraheme net sales $75 - $85 $80 - $87 Feraheme COGS (% of Feraheme global net sales) 14% - 16% 13% - 15% Operating expenses $80 - $85 $87 - $92 Net loss ($10 - $12) ($12 -

  24. Slide 24: 2014 Goals

    2014 Goals Maximize Feraheme opportunities Drive market share and market growth within current U.S. IDA-CKD indication Optimize net revenue per gram Potential label expansion: broad IDA Determine regulatory path forward in U.S. Expected CHMP opinion – 4Q14 Pursue IV iron market expansion initiatives

  25. Slide 25: Well positioned for success in 2014... and beyond.

    Well positioned for success in 2014. . . and beyond.

Amag Pharmaceuticals — Q2 2014 Earnings Presentation on 6ix